WO2008137658A1 - Otitis externa - Google Patents
Otitis externa Download PDFInfo
- Publication number
- WO2008137658A1 WO2008137658A1 PCT/US2008/062393 US2008062393W WO2008137658A1 WO 2008137658 A1 WO2008137658 A1 WO 2008137658A1 US 2008062393 W US2008062393 W US 2008062393W WO 2008137658 A1 WO2008137658 A1 WO 2008137658A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- otitis externa
- steroid
- antiseptic
- mammal
- symptom
- Prior art date
Links
- 206010033072 otitis externa Diseases 0.000 title claims abstract description 84
- 150000003431 steroids Chemical class 0.000 claims abstract description 54
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 39
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 23
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 23
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 11
- 239000011630 iodine Substances 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims description 54
- 208000024891 symptom Diseases 0.000 claims description 34
- 230000002829 reductive effect Effects 0.000 claims description 24
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 229920000153 Povidone-iodine Polymers 0.000 claims description 19
- 229960001621 povidone-iodine Drugs 0.000 claims description 19
- 229940047652 ear drops Drugs 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 7
- 239000003221 ear drop Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 abstract description 16
- 210000000613 ear canal Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000006196 drop Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010033078 Otitis media Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 206010033101 Otorrhoea Diseases 0.000 description 5
- 239000012459 cleaning agent Substances 0.000 description 5
- 201000009890 sinusitis Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011538 cleaning material Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000003454 tympanic membrane Anatomy 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229940064804 betadine Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 3
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010052137 Ear discomfort Diseases 0.000 description 2
- 206010014020 Ear pain Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940021285 ciprodex Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- -1 halbetasol Chemical compound 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000011643 malignant otitis externa Diseases 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010062067 Perichondritis Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940123317 Sulfonamide antibiotic Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000026231 acute otitis externa Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960002794 prednicarbate Drugs 0.000 description 1
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Definitions
- This document relates to methods and materials involved in treating otitis externa.
- this document relates to methods and materials involved in using a steroid (e.g., dexamethasone) and an antiseptic (e.g., iodine) to treat otitis externa.
- a steroid e.g., dexamethasone
- an antiseptic e.g., iodine
- Otitis externa is an inflammation, irritation, or infection of the outer ear and ear canal that can affect mammals in all age groups, particularly older pediatric and young adult populations.
- a bacterial infection is typically responsible for causing otitis externa, but the disease may also be associated with a fungal infection or a variety of noninfectious systemic or local dermato logic processes.
- otitis externa can be caused by moisture trapped in the ear canal after swimming or bathing that results in maceration of the skin and provides a breeding ground for microbes such as
- Otitis externa is sometimes referred to as "swimmer's ear.” Otitis externa also can be caused by trauma to the ear canal that allows invasion of bacteria into the damaged skin. Such trauma can occur during attempts at cleaning the ear with a cotton swab or paper clip.
- otitis externa otalgia
- otorrhea discharge in or coming from the external auditory canal.
- the ear discomfort can range from pruritus to severe pain that is exacerbated by motion of the ear, including chewing. If inflammation causes sufficient swelling to occlude the external auditory canal, loss of hearing can occur. If severe, the infection may spread and cause lymphadenitis or cellulitis of the face or neck.
- necrotizing or malignant otitis externa which is a life-threatening extension of external otitis into the mastoid or temporal bone.
- necrotizing otitis externa is an osteomyelitis that occurs most often in elderly patients with diabetes mellitus.
- all immunocompromised mammals especially those infected with an immunodeficiency virus, are at risk.
- This document provides methods and materials related to treating otitis externa.
- this document provides methods and materials for using a steroid (e.g., dexamethasone) and an antiseptic (e.g., povidone-iodine) to treat otitis externa.
- a steroid e.g., dexamethasone
- an antiseptic e.g., povidone-iodine
- the methods and materials provided herein can be used to reduce the severity of a symptom of otitis externa and/or to reduce progression of otitis externa. Reducing the severity of a symptom or the progression of otitis externa can decrease morbidity associated with otitis externa and inhibit the spread of infectious otitis externa.
- this document is based in part on the discovery that a combination of the antiseptic povidone-iodine and the steroid dexamethasone (Betadex) can be used to treat otitis externa.
- a combination can destroy or inhibit the growth of a broad spectrum of bacteria as well as fungi and viruses.
- use of an antiseptic and a steroid to treat otitis externa can be associated with a low level of bacterial resistance. Additional advantages of using an antiseptic such as povidone - iodine and a steroid such as dexamethasone to treat otitis externa can include improved efficacy, low cost, and anti-inflammatory properties.
- the methods and materials provided herein can be administered to a mammal (e.g., an ear and/or sinonasal cavity of the mammal) to treat otitis externa, otitis media, a sinus infection, and/or a nasal infection.
- a mammal e.g., an ear and/or sinonasal cavity of the mammal
- one aspect of this document features a method for treating a mammal having otitis externa.
- the method comprises, or consists essentially of, administering to the mammal an antiseptic and a steroid under conditions wherein a symptom of otitis externa is reduced.
- the mammal can be a human.
- the otitis externa can be caused by bacteria.
- the otitis externa can be caused by fungi.
- a composition comprising, or consisting essentially of, the antiseptic and the steroid can be administered to the mammal.
- the antiseptic can be iodine.
- the iodine can be a povidone-iodine.
- the steroid can be dexamethasone.
- the antiseptic and the steroid can be administered as ear drops.
- the symptom can be reduced by 25 percent.
- the symptom can be reduced by 50 percent.
- the symptom can be reduced by 75 percent.
- the symptom can be reduced by 100 percent.
- Another aspect of this document features a method for treating a mammal having otitis externa, otitis media, a nasal infection, a sinus infection, or a combination thereof.
- the method comprises, or consists essentially of, administering to the mammal an antiseptic and a steroid under conditions wherein a symptom of otitis externa, otitis media, a nasal infection, or a sinus infection is reduced.
- the mammal can be a human.
- the otitis externa, otitis media, nasal infection, or sinus infection can be caused by bacteria.
- the otitis externa, otitis media, nasal infection, or sinus infection can be caused by fungi.
- a composition comprising, or consisting essentially of, the antiseptic and the steroid can be administered to the mammal.
- the antiseptic can be iodine.
- the iodine can be a povidone-iodine.
- the steroid can be dexamethasone.
- the antiseptic and the steroid can be administered as ear drops.
- the symptom can be reduced by 25 percent.
- the symptom can be reduced by 50 percent.
- the symptom can be reduced by 75 percent.
- the symptom can be reduced by 100 percent.
- This document provides methods and materials related to treating otitis externa in mammals.
- this document provides methods and materials related to the use of an antiseptic (e.g., povidone -iodine) and a steroid (e.g., dexamethasone) to treat otitis externa in a mammal.
- the methods and materials provided herein can be used to treat otitis externa in any type of mammal including, without limitation, mice, rats, dogs, cats, horses, cows, pigs, monkeys, and humans.
- Any type of otitis externa can be treated.
- otitis externa caused by one or more bacteria, viruses, fungi, or combinations thereof can be treated.
- non- infectious otitis externa can be treated.
- otitis externa can be treated by administering an antiseptic and a steroid to a mammal having otitis externa.
- an antiseptic and a steroid can be used to treat otitis externa upon administration either individually or in combination.
- a mammal having otitis externa can be treated by administering an antiseptic and a steroid individually.
- otitis externa can be treated by administering a composition containing an antiseptic and a steroid to a mammal.
- Any antiseptic can be used in combination with any steroid to treat otitis externa including, without limitation iodine or povidone-iodine.
- Non-limiting examples of steroids include dexamethasone, clobetasol, betamethasone, rudetasol, diflorasone, fluocinonide, halcinonide, amcinonide, desoximetasone, triamcinolone, mometasone, fluticasone, fluocinolone, hydrocortisone, flurandrenolide, triamcinalone, desonide, and prednicarbate.
- An antiseptic and a steroid can be obtained or produced by any appropriate method.
- an antiseptic and a steroid can be chemically synthesized and purified using standard organic synthetic chemistry methods.
- An antiseptic and a steroid can also be obtained from a commercial source.
- dexamethasone sodium phosphate powder can be obtained from Gallipot, located at 2400 Pilot Knob Road, St. Paul, MN, 55120.
- a 10% solution of povidone-iodine can be obtained from Humco, located at 7400 Alumax Drive, Texarkana, TX, 75501.
- An antiseptic and a steroid can be combined to produce a composition useful for treating otitis externa.
- a composition can be prepared that contains 10% povidone-iodine and 0.1% dexamethasone.
- a composition containing an antiseptic and a steroid can be in any appropriate form.
- a composition provided herein can be in the form of a gel or solution for topical administration or administration in the ear (e.g., ear drops).
- a composition can contain additional ingredients including, without limitation, pharmaceutically acceptable excipients.
- a pharmaceutically acceptable excipient can be, for example, water, sodium hydroxide, or a surfactant.
- an antiseptic and a steroid can be administered topically or in the form of ear drops.
- an antiseptic and a steroid can be administered by different routes.
- an antiseptic can be administered as topical ear drops and a steroid can be administered orally.
- an antiseptic and a steroid can be administered to an ear or sinonasal cavity either individually or as a combination.
- the mammal Before administering an antiseptic and a steroid to a mammal, the mammal can be assessed to determine whether or not the mammal has otitis externa. Any appropriate method can be used to determine whether or not a mammal has otitis externa.
- a mammal e.g., human
- a mammal can be identified as having otitis externa when the ear canal of the mammal appears red and swollen or has an eczema- like appearance with scaly shedding of skin.
- increased pain upon touching or moving the outer ear can indicate that a mammal has otitis externa.
- Difficulty visualizing the eardrum with an otoscope due to narrowing of the ear canal from inflammation and the presence of drainage and debris also can indicate that a mammal has otitis externa.
- exudate from the ear of a mammal can be cultured to identify bacteria or fungi causing otitis externa in the mammal. After identifying a mammal as having otitis externa, the mammal can be administered an antiseptic and a steroid.
- An antiseptic and a steroid can be administered to a mammal in any amount, at any frequency, and for any duration effective to achieve a desired outcome (e.g., to reduce the severity of a symptom of otitis externa or to reduce spreading of infectious otitis externa).
- a desired outcome e.g., to reduce the severity of a symptom of otitis externa or to reduce spreading of infectious otitis externa.
- an antiseptic and a steroid can be administered to a mammal having otitis media to reduce the severity of a symptom or to reduce the progression rate of otitis externa by 5, 10, 25, 50, 75, 100, or more percent.
- the severity of a symptom can be reduced in a mammal such that the symptom is no longer detected by the mammal.
- the progression of infectious otitis externa can be reduced such that no additional progression is detected. Any method can be used to determine whether or not the severity of a symptom or the progression rate of otitis externa is reduced. For example, a mammal having otitis externa can be questioned about pain or discomfort before and after treatment to determine whether a symptom of otitis externa (e.g., ear pain or ear itching) is reduced.
- a symptom of otitis externa e.g., ear pain or ear itching
- a mammal can be observed or tested for the severity of a symptom of otitis externa (e.g., ear discharge, sensitivity of the ear to pressure, sensitivity of the earlobe to touch, or reduced hearing) before and after treatment with an antiseptic and a steroid to determine whether or not the severity of a symptom is reduced.
- a symptom of otitis externa e.g., ear discharge, sensitivity of the ear to pressure, sensitivity of the earlobe to touch, or reduced hearing
- an otolaryngologist can assess the severity of otitis externa (e.g., by performing a physical examination and assigning a Grade 1 to 4 score) before and after treatment to determine whether the severity of a symptom is reduced.
- a physical examination can be performed at different time points to determine the amount of erythema and/or edema in and around the ear canal.
- the amount of erythema and edema observed at different time points can be compared to assess the progression rate.
- the progression rate can be determined again over another time interval to determine whether or not the progression rate has decreased.
- an effective amount of an antiseptic and a steroid can be any amount that reduces the severity of a symptom or the progression of otitis externa without producing significant toxicity to the mammal.
- an effective amount of an antiseptic such as povidone -iodine can be from about 5% to about 20% (e.g., about 10%) povidone- iodine in an otic drop formulation.
- An effective amount of a steroid such as dexamethasone can be from about 0.05% to about 0.20% (e.g., about 0.10%) dexamethasone in an otic drop formulation.
- an effective amount of an antiseptic such as povidone-iodine and a steroid such as dexamethasone can be from about 2 drops to about 8 drops of an otic drop formulation containing about 10% povidone-iodine and about 0.10% dexamethasone applied to the ear. If a particular mammal fails to respond to a particular amount, then the amount of one or more of the antiseptic and the steroid can be increased by, for example, two fold. After receiving this higher concentration, the mammal can be monitored for both responsiveness to the treatment and toxicity symptoms, and adjustments made accordingly. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the mammal's response to treatment.
- the frequency of administration can be any frequency that reduces the severity of a symptom or progression rate of otitis externa without producing significant toxicity to the mammal.
- the frequency of administration can be from about once daily to about four times daily (e.g., about twice daily).
- the frequency of administration can remain constant or can be variable during the duration of treatment.
- the frequency of administration of an antiseptic and a steroid can be the same or can differ.
- an antiseptic can be administered three times daily, while a steroid can be administered once daily.
- a course of treatment with an antiseptic and a steroid can include rest periods.
- an antiseptic and a steroid can be administered over a two week period followed by a two week rest period, and such a regimen can be repeated multiple times.
- the effective amount various factors can influence the actual frequency of administration used for a particular application. For example, the effective amount, duration of treatment, use of multiple treatment agents, route of administration, immunocompetency of the mammal, and severity of the otitis externa may require an increase or decrease in administration frequency.
- An effective duration for administering a composition provided herein can be any duration that reduces the severity of a symptom or the progression rate of otitis externa without producing significant toxicity to the mammal.
- the effective duration can vary from several days to several weeks, months, or years.
- the effective duration for the treatment of otitis externa can range in duration from several days to several weeks.
- an effective duration can be for as long as an individual mammal is alive. Multiple factors can influence the actual effective duration used for a particular treatment.
- an effective duration can vary with the frequency of administration, effective amount, use of multiple treatment agents, route of administration, immunocompetency of the mammal, and severity of the otitis externa.
- an antiseptic and a steroid e.g., a composition containing an antiseptic and a steroid
- the mammal can be monitored to determine whether or not the otitis externa was treated.
- a mammal can be assessed after treatment to determine whether or not a symptom of otitis externa was reduced (e.g., stopped).
- any method can be used to assess symptoms and progression of otitis externa.
- a composition disclosed herein such as a composition containing iodine and a steroid such as dexamethasone can be provided together with a cleaning material (e.g., a wipe, tissue, or cloth) and/or a cleaning agent that can be used to remove any excess iodine from skin or clothing.
- a cleaning material e.g., a wipe, tissue, or cloth
- cleaning agents include, without limitation, solutions containing alcohol, ascorbic acid, and/or salicylic acid (see, for example, U.S. Patent No. 6,309,471).
- a cleaning material and a cleaning agent can be combined together in one container in a ready to use form.
- a cleaning material such as a wipe can be impregnated in a cleaning agent such as an organic (e.g., ethanol) or aqueous solution containing salicylic acid.
- a cleaning material, a cleaning agent, and a composition containing an antiseptic and a steroid can be provided in a kit.
- the kit can include informational material that can be descriptive, instructional, marketing, or other material that relates to use of the kit components.
- Example 1 Treating otitis externa with povidone-iodine and dexamethasone
- a solution containing 0.1% dexamethasone and 10% povidone-iodine was prepared as follows.
- Dexamethasone sodium phosphate powder was obtained from Gallipot (St. Paul, MN), and 1.3 grams of the powder, corresponding to 1 gram of dexamethasone, were weighed out using an analytical balance.
- a 10% solution of povidone-iodine was obtained from Humco (Texarkana, TX).
- the dexamethasone sodium phosphate powder (1.3 grams) was mixed into one liter of the 10% povidone- iodine solution on a stir plate at a low spin rate for about five minutes. The mixture was allowed to stand until the foam subsided.
- the solution was then filtered in a laminar flow hood using aseptic technique.
- a Baxa pump and a Millex-GP 50 mm, 0.22 micron filter (Millipore, Billerica, MA) were used to filter the solution into 30 mL sterile amber plastic dropper bottles (Healthcare Logistics, Circleville, OH).
- the filter was changed after every fourth bottle was filled. Each bottle was capped immediately after being filled and labeled.
- Sterility testing was performed using the Millipore system. Filters were wetted using 100 mL of a 0.9% sodium chloride solution. A dropper bottle to be tested was wiped with alcohol and allowed to dry. A needle was inserted into the bottle, and the solution was filtered. The filter was rinsed three times with 200 mL of 0.9% sodium chloride (100 mL per canister). The caps were placed on the outlets of the canisters. One of the tubing lines was clamped off. Growth media (100 mL) was added to a canister. The clamp was switched to the other tubing line, and 100 mL of the second growth media was placed into the other canister. Each canister was prepared for incubation. A "Quality Assurance for Sterile Formulations" form was completed, and each canister was marked with identifying information. The canisters were incubated and monitored for microbial growth. No microbial growth was observed after 90 days of incubation.
- a study is performed to determine the effectiveness and adverse side effects of Betadine / Dexamethasone combination otic drops at a concentration of 10% Povidone- Iodine/0.15% Dexamethasone applied as otic drops (four drops) in an effected ear twice daily for seven days.
- the otic drops are applied for the treatment of uncomplicated AOE.
- the study population consists of 45 individuals eighteen years or older presenting with AOE, manifested by pain, inflammation, and tenderness of less than two weeks duration in one or both ears and who desire to participate in a clinical research study of this type. All patients are evaluated by an Otolaryngology resident, board certified Otolaryngologist, or experienced Otolaryngology Physician Assistant.
- Exclusion criteria include previous treatment, in the past two weeks, with systemic antibiotics, or ototopical preparations of any kind; a history of diabetes mellitus with or without signs of malignant otitis externa; pregnancy (female patients of child bearing age undergo a urine pregnancy test); known tympanic membrane perforation, inability to assess for tympanic membrane perforation, or current presence of a ventilating tube; presence of concomitant acute otitis media, mastoiditis, perichondritis of the pinna or other infectious complication in addition to the acute otitis externa; known immunodeficiency or other systemic disease involving the ears; allergy or sensitivity to betadine, sulfonamide antibiotics, dexamethasone, other topical steroid intolerance, or any other ingredient in the preparation; known viral infections of the external auditory canal; and congenital
- Data are collected for a minimum of 21 days for each of the patients enrolled in the study. Patients undergo three required evaluations in the otolaryngology clinic days after initial diagnosis (on days 1, 7-10, and 21).
- Patient are assessed for efficacy using photodocumentation. Patients undergo photodocumentation with the use of a digital camera on day 1 and day 7-10. If patients experience persistent infection, documentation is also obtained on day 21. The degree of inflammation of the external canal is also assessed using a Grading system as follows:
- a prospective randomized study is performed to compare Betadine / Dexamethasone with a Ciprodex® preparation.
- a randomized comparison group of 15 patients are assigned treatment with Ciprodex®, four drops in the affected ear twice daily for seven days. Randomization is preformed with pre-assigned envelopes.
- Statistical methods are used to analyze the data. Nominal and categorical variables are summarized by calculating frequencies and percentages, and continuously scaled variables are summarized by calculating mean, median, standard deviation and range. The demographic characteristics of the patients are summarized as well as the results of the examinations and questionnaire responses at baseline, day 7-10, and day 21. In addition, the frequency of side effects is tabulated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This document provides methods and materials related to treating otitis externa. For example, methods and materials relating to the use of an antiseptic (e.g., iodine) and a steroid (e.g., dexamethasone) to treat otitis externa are provided.
Description
OTITIS EXTERNA
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Serial No. 60/915,813, filed May 3, 2007. The entire disclosure of the earlier application is incorporated herein by reference.
BACKGROUND
1. Technical Field
This document relates to methods and materials involved in treating otitis externa. For example, this document relates to methods and materials involved in using a steroid (e.g., dexamethasone) and an antiseptic (e.g., iodine) to treat otitis externa.
2. Background Information
Otitis externa is an inflammation, irritation, or infection of the outer ear and ear canal that can affect mammals in all age groups, particularly older pediatric and young adult populations. A bacterial infection is typically responsible for causing otitis externa, but the disease may also be associated with a fungal infection or a variety of noninfectious systemic or local dermato logic processes. For example, otitis externa can be caused by moisture trapped in the ear canal after swimming or bathing that results in maceration of the skin and provides a breeding ground for microbes such as
Pseudomonas aeruginosa, Staphylococcus aureus or, less commonly, fungi such as Candida or Aspergillus species. For this reason, otitis externa is sometimes referred to as "swimmer's ear." Otitis externa also can be caused by trauma to the ear canal that allows invasion of bacteria into the damaged skin. Such trauma can occur during attempts at cleaning the ear with a cotton swab or paper clip.
Once infection is established, an inflammatory response can occur with erythema and swelling of the canal. The two most characteristic presenting symptoms of otitis externa are otalgia (ear discomfort) and otorrhea (discharge in or coming from the external auditory canal). The ear discomfort can range from pruritus to severe pain that is exacerbated by motion of the ear, including chewing. If inflammation causes sufficient
swelling to occlude the external auditory canal, loss of hearing can occur. If severe, the infection may spread and cause lymphadenitis or cellulitis of the face or neck. Complications of bacterial otitis externa include necrotizing or malignant otitis externa, which is a life-threatening extension of external otitis into the mastoid or temporal bone. Most commonly caused by Pseudomonas aeruginosa, necrotizing otitis externa is an osteomyelitis that occurs most often in elderly patients with diabetes mellitus. However, all immunocompromised mammals, especially those infected with an immunodeficiency virus, are at risk.
SUMMARY
This document provides methods and materials related to treating otitis externa. For example, this document provides methods and materials for using a steroid (e.g., dexamethasone) and an antiseptic (e.g., povidone-iodine) to treat otitis externa. The methods and materials provided herein can be used to reduce the severity of a symptom of otitis externa and/or to reduce progression of otitis externa. Reducing the severity of a symptom or the progression of otitis externa can decrease morbidity associated with otitis externa and inhibit the spread of infectious otitis externa.
As described herein, this document is based in part on the discovery that a combination of the antiseptic povidone-iodine and the steroid dexamethasone (Betadex) can be used to treat otitis externa. Such a combination can destroy or inhibit the growth of a broad spectrum of bacteria as well as fungi and viruses. In addition, since the mechanism of action of an antiseptic can differ from that of an antibiotic, use of an antiseptic and a steroid to treat otitis externa can be associated with a low level of bacterial resistance. Additional advantages of using an antiseptic such as povidone - iodine and a steroid such as dexamethasone to treat otitis externa can include improved efficacy, low cost, and anti-inflammatory properties.
In some cases, the methods and materials provided herein (e.g., a composition containing an antiseptic and a steroid) can be administered to a mammal (e.g., an ear and/or sinonasal cavity of the mammal) to treat otitis externa, otitis media, a sinus infection, and/or a nasal infection.
In general, one aspect of this document features a method for treating a mammal having otitis externa. The method comprises, or consists essentially of, administering to the mammal an antiseptic and a steroid under conditions wherein a symptom of otitis externa is reduced. The mammal can be a human. The otitis externa can be caused by bacteria. The otitis externa can be caused by fungi. A composition comprising, or consisting essentially of, the antiseptic and the steroid can be administered to the mammal. The antiseptic can be iodine. The iodine can be a povidone-iodine. The steroid can be dexamethasone. The antiseptic and the steroid can be administered as ear drops. The symptom can be reduced by 25 percent. The symptom can be reduced by 50 percent. The symptom can be reduced by 75 percent. The symptom can be reduced by 100 percent.
Another aspect of this document features a method for treating a mammal having otitis externa, otitis media, a nasal infection, a sinus infection, or a combination thereof. The method comprises, or consists essentially of, administering to the mammal an antiseptic and a steroid under conditions wherein a symptom of otitis externa, otitis media, a nasal infection, or a sinus infection is reduced. The mammal can be a human. The otitis externa, otitis media, nasal infection, or sinus infection can be caused by bacteria. The otitis externa, otitis media, nasal infection, or sinus infection can be caused by fungi. A composition comprising, or consisting essentially of, the antiseptic and the steroid can be administered to the mammal. The antiseptic can be iodine. The iodine can be a povidone-iodine. The steroid can be dexamethasone. The antiseptic and the steroid can be administered as ear drops. The symptom can be reduced by 25 percent. The symptom can be reduced by 50 percent. The symptom can be reduced by 75 percent. The symptom can be reduced by 100 percent. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials,
methods, and examples are illustrative only and not intended to be limiting.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DETAILED DESCRIPTION
This document provides methods and materials related to treating otitis externa in mammals. For example, this document provides methods and materials related to the use of an antiseptic (e.g., povidone -iodine) and a steroid (e.g., dexamethasone) to treat otitis externa in a mammal. The methods and materials provided herein can be used to treat otitis externa in any type of mammal including, without limitation, mice, rats, dogs, cats, horses, cows, pigs, monkeys, and humans. Any type of otitis externa can be treated. For example, otitis externa caused by one or more bacteria, viruses, fungi, or combinations thereof can be treated. In some cases, non- infectious otitis externa can be treated.
In general, otitis externa can be treated by administering an antiseptic and a steroid to a mammal having otitis externa. It will be appreciated that an antiseptic and a steroid can be used to treat otitis externa upon administration either individually or in combination. For example, a mammal having otitis externa can be treated by administering an antiseptic and a steroid individually. In some cases, otitis externa can be treated by administering a composition containing an antiseptic and a steroid to a mammal.
Any antiseptic can be used in combination with any steroid to treat otitis externa including, without limitation iodine or povidone-iodine. Non-limiting examples of steroids include dexamethasone, clobetasol, betamethasone, halbetasol, diflorasone, fluocinonide, halcinonide, amcinonide, desoximetasone, triamcinolone, mometasone, fluticasone, fluocinolone, hydrocortisone, flurandrenolide, triamcinalone, desonide, and prednicarbate. An antiseptic and a steroid can be obtained or produced by any appropriate method. For example, an antiseptic and a steroid can be chemically synthesized and purified using standard organic synthetic chemistry methods. An antiseptic and a steroid can also be obtained from a commercial source. For example,
dexamethasone sodium phosphate powder can be obtained from Gallipot, located at 2400 Pilot Knob Road, St. Paul, MN, 55120. A 10% solution of povidone-iodine can be obtained from Humco, located at 7400 Alumax Drive, Texarkana, TX, 75501.
An antiseptic and a steroid can be combined to produce a composition useful for treating otitis externa. For example, a composition can be prepared that contains 10% povidone-iodine and 0.1% dexamethasone. A composition containing an antiseptic and a steroid can be in any appropriate form. For example, a composition provided herein can be in the form of a gel or solution for topical administration or administration in the ear (e.g., ear drops). In some cases, a composition can contain additional ingredients including, without limitation, pharmaceutically acceptable excipients. A pharmaceutically acceptable excipient can be, for example, water, sodium hydroxide, or a surfactant.
Any appropriate method can be used to administer an antiseptic and a steroid to a mammal. For example, an antiseptic and a steroid can be administered topically or in the form of ear drops. In some cases, an antiseptic and a steroid can be administered by different routes. For example, an antiseptic can be administered as topical ear drops and a steroid can be administered orally. In some cases, an antiseptic and a steroid can be administered to an ear or sinonasal cavity either individually or as a combination.
Before administering an antiseptic and a steroid to a mammal, the mammal can be assessed to determine whether or not the mammal has otitis externa. Any appropriate method can be used to determine whether or not a mammal has otitis externa. For example, a mammal (e.g., human) can be identified as having otitis externa when the ear canal of the mammal appears red and swollen or has an eczema- like appearance with scaly shedding of skin. In some cases, increased pain upon touching or moving the outer ear can indicate that a mammal has otitis externa. Difficulty visualizing the eardrum with an otoscope due to narrowing of the ear canal from inflammation and the presence of drainage and debris also can indicate that a mammal has otitis externa. In some cases, exudate from the ear of a mammal can be cultured to identify bacteria or fungi causing otitis externa in the mammal. After identifying a mammal as having otitis externa, the mammal can be administered an antiseptic and a steroid. An antiseptic and a steroid can be administered
to a mammal in any amount, at any frequency, and for any duration effective to achieve a desired outcome (e.g., to reduce the severity of a symptom of otitis externa or to reduce spreading of infectious otitis externa). In some cases, an antiseptic and a steroid can be administered to a mammal having otitis media to reduce the severity of a symptom or to reduce the progression rate of otitis externa by 5, 10, 25, 50, 75, 100, or more percent. For example, the severity of a symptom can be reduced in a mammal such that the symptom is no longer detected by the mammal. In some cases, the progression of infectious otitis externa can be reduced such that no additional progression is detected. Any method can be used to determine whether or not the severity of a symptom or the progression rate of otitis externa is reduced. For example, a mammal having otitis externa can be questioned about pain or discomfort before and after treatment to determine whether a symptom of otitis externa (e.g., ear pain or ear itching) is reduced. In some cases, a mammal can be observed or tested for the severity of a symptom of otitis externa (e.g., ear discharge, sensitivity of the ear to pressure, sensitivity of the earlobe to touch, or reduced hearing) before and after treatment with an antiseptic and a steroid to determine whether or not the severity of a symptom is reduced. In some cases, an otolaryngologist can assess the severity of otitis externa (e.g., by performing a physical examination and assigning a Grade 1 to 4 score) before and after treatment to determine whether the severity of a symptom is reduced. To determine whether or not progression of otitis externa is reduced, a physical examination can be performed at different time points to determine the amount of erythema and/or edema in and around the ear canal. The amount of erythema and edema observed at different time points can be compared to assess the progression rate. After treatment as described herein, the progression rate can be determined again over another time interval to determine whether or not the progression rate has decreased.
An effective amount of an antiseptic and a steroid can be any amount that reduces the severity of a symptom or the progression of otitis externa without producing significant toxicity to the mammal. For example, an effective amount of an antiseptic such as povidone -iodine can be from about 5% to about 20% (e.g., about 10%) povidone- iodine in an otic drop formulation. An effective amount of a steroid such as dexamethasone can be from about 0.05% to about 0.20% (e.g., about 0.10%)
dexamethasone in an otic drop formulation. In addition, an effective amount of an antiseptic such as povidone-iodine and a steroid such as dexamethasone can be from about 2 drops to about 8 drops of an otic drop formulation containing about 10% povidone-iodine and about 0.10% dexamethasone applied to the ear. If a particular mammal fails to respond to a particular amount, then the amount of one or more of the antiseptic and the steroid can be increased by, for example, two fold. After receiving this higher concentration, the mammal can be monitored for both responsiveness to the treatment and toxicity symptoms, and adjustments made accordingly. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the mammal's response to treatment. Various factors can influence the actual effective amount used for a particular application. For example, the frequency of administration, duration of treatment, use of multiple treatment agents, route of administration, immunocompetency of the mammal, and severity of the otitis externa may require an increase or decrease in the actual effective amount administered. The frequency of administration can be any frequency that reduces the severity of a symptom or progression rate of otitis externa without producing significant toxicity to the mammal. For example, the frequency of administration can be from about once daily to about four times daily (e.g., about twice daily). The frequency of administration can remain constant or can be variable during the duration of treatment. In addition, the frequency of administration of an antiseptic and a steroid can be the same or can differ. For example, an antiseptic can be administered three times daily, while a steroid can be administered once daily. A course of treatment with an antiseptic and a steroid can include rest periods. For example, an antiseptic and a steroid can be administered over a two week period followed by a two week rest period, and such a regimen can be repeated multiple times. As with the effective amount, various factors can influence the actual frequency of administration used for a particular application. For example, the effective amount, duration of treatment, use of multiple treatment agents, route of administration, immunocompetency of the mammal, and severity of the otitis externa may require an increase or decrease in administration frequency. An effective duration for administering a composition provided herein can be any duration that reduces the severity of a symptom or the progression rate of otitis externa
without producing significant toxicity to the mammal. Thus, the effective duration can vary from several days to several weeks, months, or years. In general, the effective duration for the treatment of otitis externa can range in duration from several days to several weeks. In some cases, an effective duration can be for as long as an individual mammal is alive. Multiple factors can influence the actual effective duration used for a particular treatment. For example, an effective duration can vary with the frequency of administration, effective amount, use of multiple treatment agents, route of administration, immunocompetency of the mammal, and severity of the otitis externa.
After administering an antiseptic and a steroid (e.g., a composition containing an antiseptic and a steroid) provided herein to a mammal, the mammal can be monitored to determine whether or not the otitis externa was treated. For example, a mammal can be assessed after treatment to determine whether or not a symptom of otitis externa was reduced (e.g., stopped). As described herein, any method can be used to assess symptoms and progression of otitis externa. A composition disclosed herein such as a composition containing iodine and a steroid such as dexamethasone can be provided together with a cleaning material (e.g., a wipe, tissue, or cloth) and/or a cleaning agent that can be used to remove any excess iodine from skin or clothing. Examples of cleaning agents include, without limitation, solutions containing alcohol, ascorbic acid, and/or salicylic acid (see, for example, U.S. Patent No. 6,309,471). A cleaning material and a cleaning agent can be combined together in one container in a ready to use form. For example, a cleaning material such as a wipe can be impregnated in a cleaning agent such as an organic (e.g., ethanol) or aqueous solution containing salicylic acid. In addition, a cleaning material, a cleaning agent, and a composition containing an antiseptic and a steroid can be provided in a kit. The kit can include informational material that can be descriptive, instructional, marketing, or other material that relates to use of the kit components.
The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
EXAMPLES
Example 1 - Treating otitis externa with povidone-iodine and dexamethasone
A solution containing 0.1% dexamethasone and 10% povidone-iodine was prepared as follows. Dexamethasone sodium phosphate powder was obtained from Gallipot (St. Paul, MN), and 1.3 grams of the powder, corresponding to 1 gram of dexamethasone, were weighed out using an analytical balance. A 10% solution of povidone-iodine was obtained from Humco (Texarkana, TX). The dexamethasone sodium phosphate powder (1.3 grams) was mixed into one liter of the 10% povidone- iodine solution on a stir plate at a low spin rate for about five minutes. The mixture was allowed to stand until the foam subsided. The solution was then filtered in a laminar flow hood using aseptic technique. A Baxa pump and a Millex-GP 50 mm, 0.22 micron filter (Millipore, Billerica, MA) were used to filter the solution into 30 mL sterile amber plastic dropper bottles (Healthcare Logistics, Circleville, OH). The filter was changed after every fourth bottle was filled. Each bottle was capped immediately after being filled and labeled.
Sterility testing was performed using the Millipore system. Filters were wetted using 100 mL of a 0.9% sodium chloride solution. A dropper bottle to be tested was wiped with alcohol and allowed to dry. A needle was inserted into the bottle, and the solution was filtered. The filter was rinsed three times with 200 mL of 0.9% sodium chloride (100 mL per canister). The caps were placed on the outlets of the canisters. One of the tubing lines was clamped off. Growth media (100 mL) was added to a canister. The clamp was switched to the other tubing line, and 100 mL of the second growth media was placed into the other canister. Each canister was prepared for incubation. A "Quality Assurance for Sterile Formulations" form was completed, and each canister was marked with identifying information. The canisters were incubated and monitored for microbial growth. No microbial growth was observed after 90 days of incubation.
A study is performed to determine the effectiveness and adverse side effects of Betadine / Dexamethasone combination otic drops at a concentration of 10% Povidone- Iodine/0.15% Dexamethasone applied as otic drops (four drops) in an effected ear twice daily for seven days. The otic drops are applied for the treatment of uncomplicated AOE.
The study population consists of 45 individuals eighteen years or older presenting with AOE, manifested by pain, inflammation, and tenderness of less than two weeks duration in one or both ears and who desire to participate in a clinical research study of this type. All patients are evaluated by an Otolaryngology resident, board certified Otolaryngologist, or experienced Otolaryngology Physician Assistant. All members of the study population have intact tympanic membranes (no middle ear exposure). Exclusion criteria include previous treatment, in the past two weeks, with systemic antibiotics, or ototopical preparations of any kind; a history of diabetes mellitus with or without signs of malignant otitis externa; pregnancy (female patients of child bearing age undergo a urine pregnancy test); known tympanic membrane perforation, inability to assess for tympanic membrane perforation, or current presence of a ventilating tube; presence of concomitant acute otitis media, mastoiditis, perichondritis of the pinna or other infectious complication in addition to the acute otitis externa; known immunodeficiency or other systemic disease involving the ears; allergy or sensitivity to betadine, sulfonamide antibiotics, dexamethasone, other topical steroid intolerance, or any other ingredient in the preparation; known viral infections of the external auditory canal; and congenital abnormalities of the external auditory canal, or exostoses.
Data are collected for a minimum of 21 days for each of the patients enrolled in the study. Patients undergo three required evaluations in the otolaryngology clinic days after initial diagnosis (on days 1, 7-10, and 21).
Table 1. Schedule of Study Events
Patient are assessed for efficacy using photodocumentation. Patients undergo photodocumentation with the use of a digital camera on day 1 and day 7-10. If patients
experience persistent infection, documentation is also obtained on day 21. The degree of inflammation of the external canal is also assessed using a Grading system as follows:
1. Normal.
2. Mild: otorrhea with out external canal swelling. 3. Moderate: otorrhea with external canal swelling leading to partial visual obstruction of the tympanic membrane. 4. Severe: otorrhea with complete external auditory canal obstruction.
Investigator unable to see the tympanic membrane without dilation of the ear canal. The degree of inflammation is documented on day 1, 7-10, and day 21 as needed for persistent infections. Evidence of purulence and discharge is documented as part of the evaluation. In addition, a questionnaire is filled out on day 1 of presentation to assess whether the patient meets study inclusion criteria. Another questionnaire is administered on day 7-10 and possibly on day 21 if the patient has persistent symptoms. Two board certified otolaryngologists assess the severity of infection by reviewing the documented pictures and assigning a Grade 1 to 4 score. The reviewer is blinded to the point in the treatment cycle the pictures were taken. Referred patients are seen by a dedicated Otolaryngology professional, either a board certified otolaryngologist, Otolaryngology resident, or experienced Otolaryngology Physician Assistant. Pre-treatment and post- treatment gram stains, cultures, and bacterial sensitivities are obtained.
A prospective randomized study is performed to compare Betadine / Dexamethasone with a Ciprodex® preparation. A randomized comparison group of 15 patients are assigned treatment with Ciprodex®, four drops in the affected ear twice daily for seven days. Randomization is preformed with pre-assigned envelopes. Statistical methods are used to analyze the data. Nominal and categorical variables are summarized by calculating frequencies and percentages, and continuously scaled variables are summarized by calculating mean, median, standard deviation and range. The demographic characteristics of the patients are summarized as well as the results of the examinations and questionnaire responses at baseline, day 7-10, and day 21. In addition, the frequency of side effects is tabulated.
OTHER EMBODIMENTS
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims
1. A method for treating a mammal having otitis externa, the method comprising administering to the mammal an antiseptic and a steroid under conditions wherein a symptom of otitis externa is reduced.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the otitis externa is caused by bacteria.
4. The method of claim 1 , wherein the otitis externa is caused by fungi.
5. The method of claim 1, wherein a composition comprising the antiseptic and the steroid is administered to the mammal.
6. The method of claim 1, wherein the antiseptic is iodine.
7. The method of claim 6, wherein the iodine is a povidone -iodine.
8. The method of claim 2, wherein the steroid is dexamethasone.
9. The method of claim 1, wherein the antiseptic and the steroid are administered as ear drops.
10. The method of claim 1 , wherein the symptom is reduced by 25 percent.
11. The method of claim 1 , wherein the symptom is reduced by 50 percent.
12. The method of claim 1 , wherein the symptom is reduced by 75 percent.
13. The method of claim 1 , wherein the symptom is reduced by 100 percent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91581307P | 2007-05-03 | 2007-05-03 | |
US60/915,813 | 2007-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008137658A1 true WO2008137658A1 (en) | 2008-11-13 |
Family
ID=39943943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/062393 WO2008137658A1 (en) | 2007-05-03 | 2008-05-02 | Otitis externa |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008137658A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2400842A1 (en) * | 2009-02-27 | 2012-01-04 | Foresight Biotherapeutics, Inc. | Otic compositions useful for the treatment of infections of the internal and external ear in mammals |
US8765724B2 (en) | 2006-03-14 | 2014-07-01 | Cls Pharmaceuticals, Inc. | Methods of using ophthalmic compositions comprising povidone-iodine |
US20140219949A1 (en) * | 2011-06-22 | 2014-08-07 | Jiangsu Deda Pharmaceuticals Co. Ltd | Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401651A (en) * | 1979-04-18 | 1983-08-30 | Knutson Richard A | Wound-healing compositions containing povidone-iodine |
US5061729A (en) * | 1988-06-08 | 1991-10-29 | Biogal Gyogyszergyar | Pharmaceutical composition and process for preparing the same |
US5879717A (en) * | 1993-02-10 | 1999-03-09 | Rita McConn-Stern | Wound healing compositions containing iodine and sucrose |
US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
-
2008
- 2008-05-02 WO PCT/US2008/062393 patent/WO2008137658A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401651A (en) * | 1979-04-18 | 1983-08-30 | Knutson Richard A | Wound-healing compositions containing povidone-iodine |
US5061729A (en) * | 1988-06-08 | 1991-10-29 | Biogal Gyogyszergyar | Pharmaceutical composition and process for preparing the same |
US5879717A (en) * | 1993-02-10 | 1999-03-09 | Rita McConn-Stern | Wound healing compositions containing iodine and sucrose |
US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765724B2 (en) | 2006-03-14 | 2014-07-01 | Cls Pharmaceuticals, Inc. | Methods of using ophthalmic compositions comprising povidone-iodine |
US10849928B2 (en) | 2006-03-14 | 2020-12-01 | Clarus Cls Holdings, Llc | Methods of using ophthalmic compositions comprising povidone-iodine |
CN105362286A (en) * | 2009-02-27 | 2016-03-02 | 前瞻生物治疗公司 | Otic compositions for the treatment of infections of the internal and external ear in mammals |
EP2400842A4 (en) * | 2009-02-27 | 2013-08-28 | Foresight Biotherapeutics Inc | Otic compositions useful for the treatment of infections of the internal and external ear in mammals |
JP2015083589A (en) * | 2009-02-27 | 2015-04-30 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | Otic compositions useful for treatment of infections of internal and external ear in mammals |
EP2400842A1 (en) * | 2009-02-27 | 2012-01-04 | Foresight Biotherapeutics, Inc. | Otic compositions useful for the treatment of infections of the internal and external ear in mammals |
AU2010218108B2 (en) * | 2009-02-27 | 2016-07-07 | Takeda Pharmaceutical Company Limited | Otic compositions useful for the treatment of infections of the internal and external ear in mammals |
JP2017031202A (en) * | 2009-02-27 | 2017-02-09 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | Otic compositions useful in treatment of infections of internal and external ear in mammals |
AU2016203574B2 (en) * | 2009-02-27 | 2017-08-31 | Takeda Pharmaceutical Company Limited | Otic compositions useful for the treatment of infections of the internal and external ear in mammals |
EP3673736A1 (en) * | 2009-02-27 | 2020-07-01 | Foresight Biotherapeutics, Inc. | Otic compositions useful for the treatment of infections of the internal and external ear in mammals |
CN102333444A (en) * | 2009-02-27 | 2012-01-25 | 前瞻生物治疗公司 | Be used to treat mammiferous interior ear and use composition with external ear infection |
US20140219949A1 (en) * | 2011-06-22 | 2014-08-07 | Jiangsu Deda Pharmaceuticals Co. Ltd | Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases |
US11986491B2 (en) * | 2011-06-22 | 2024-05-21 | Iview Therapeutics, Inc. | Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6908568B2 (en) | Substances and methods for treating conditions associated with pathogenic biofilms | |
KR101176380B1 (en) | Compositions and methods for treating demodex infestations | |
Kaushik et al. | Interventions for acute otitis externa | |
Marple et al. | Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions | |
RU2295346C2 (en) | Method for treating middle ear infection cases | |
JP2019189613A (en) | Materials and methods for controlling infections | |
CN103269686B (en) | Contact lens ophthalmic composition | |
BRPI0710615A2 (en) | methods and compositions for the treatment of infectious or infectious colonization of the eyelid, ocular surface, skin or ear | |
RU2708329C2 (en) | Stem cell material, compositions and methods of use | |
US11154578B2 (en) | Compositions and methods of use | |
Wall et al. | Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections: a review of the literature | |
US9662356B1 (en) | Propolis-metal nanoparticle composition and methods of use | |
Mulcahy et al. | Post-injection endophthalmitis rates with reduced povidone-iodine prophylaxis in patients with self-reported iodine sensitivity | |
WO2008137658A1 (en) | Otitis externa | |
Mencucci et al. | Azithromycin: assessment of intrinsic cytotoxic effects on corneal epithelial cell cultures | |
Barac et al. | Chronic rhinosinusitis: association of recalcitrant nasal polyposis and fungal finding in polyp’s single-cell suspension | |
Kanclerz et al. | Low efficacy of hypochlorous acid solution compared to povidone-iodine in cataract surgery antisepsis | |
US20100040657A1 (en) | Gentle, non-irritating, non-alcoholic skin disinfectant | |
Kelly | Aspergillosis of the nose and maxillary antrum | |
CN102078325A (en) | Nasal composition containing povidone iodine and cyclodextrin inclusion of glucocorticoid | |
JP2019532991A (en) | Materials and methods for biofilm control | |
US10016375B2 (en) | Materials and methods for controlling infections | |
Ruddy et al. | Optimum management of the discharging ear | |
Malik et al. | Prevalence of fungal infection in nasal polyps | |
Gupta et al. | To study the role of antibiotic+ steroid irrigation of the middle ear in active chronic otitis media with small perforation and pulsatile discharge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08747483 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08747483 Country of ref document: EP Kind code of ref document: A1 |